{
  "docId": "019dd923-622c-750b-8b9a-8c03a48e7d6f",
  "docSlug": "86e21d9d1e23",
  "documentTitle": "PMV Pharmaceuticals (PMVP)",
  "authorId": "60_Wolfpack_Research",
  "authorName": "Wolfpack Research",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2022-05-19 00:00:00",
  "orientation": "portrait",
  "aspectRatio": 0.77272725,
  "pageNumber": 15,
  "pageCount": 19,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "villain_critique",
  "function": "name_villain",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "Includes a stock chart of Aprea (APRE) showing a significant decline, used as a comparative precedent for the author's bearish thesis on PMV Pharma.",
  "elementsJson": [
    "headline_text",
    "paragraph",
    "candlestick"
  ],
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-8c03a48e7d6f/15",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-8c03a48e7d6f",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-8c03a48e7d6f.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-8c03a48e7d6f#slide-15",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "We believe that in just a matter of a few days, PMV Pharma will head down the same path as Aprea, its stock dropped 77% on the Phase 3 failure in December 2020.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-70f9-71ae-a679-7e9d8a84328d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.29,
        "w": 0.78,
        "x": 0.11,
        "y": 0.31
      },
      "kind": "chart",
      "text": "Yahoo Finance stock chart for APRE showing a sharp decline from 2020 to 2022.",
      "attrs": null,
      "subkind": "candlestick",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2c34712f-fa20-4461-9457-71c03053e470",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "stock price: 77%",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd953-70f9-71ae-a679-801f9371fa41",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.78,
        "x": 0.11,
        "y": 0.65
      },
      "kind": "paragraph",
      "text": "We expect the market to have a similar response if PMV’s data demonstrates that the drug lacks the potency necessary for it to be approved by the FDA as an effective monotherapy.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1badbceb-c5bb-4e03-a187-e125479dbb4b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.78,
        "x": 0.11,
        "y": 0.79
      },
      "kind": "paragraph",
      "text": "We believe that PMV’s lead candidate will prove worthless... Targeting mutant p53 has been a difficult area for biopharma investors. We believe in just a matter of a few days, PMV Pharma will head down the same path as Aprea...",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9356d2ec-e573-4790-9eb5-0a275b889d04",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.78,
        "x": 0.11,
        "y": 0.72
      },
      "kind": "paragraph",
      "text": "PMV Pharma is currently trading at $13.77 per share, which equates to a market capitalization of approximately $628 million. PMV exited March 2022 with $295 million in cash, with a cash burn of approximately $18 million last quarter.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b92cbb74-311c-471b-bc78-4fe789bac893",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.78,
        "x": 0.11,
        "y": 0.16
      },
      "kind": "paragraph",
      "text": "PMV’s lead candidate reminds us of Aprea’s failed efforts with eprenetapopt (APR-246)... The lack of positive outcomes resulted in the FDA placing two separate clinical holds...",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c82e4113-f4bb-4478-a1e7-e5442397bd85",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.78,
        "x": 0.11,
        "y": 0.11
      },
      "kind": "title",
      "text": "Conclusion: PMV’s Lead Drug Candidate Will Likely Fail Due to Lack of Potency, A Dire Result for Investors",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1d52d003-fe1c-450d-858d-999ab4e34549",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "argument-from-analogy",
      "slug": null,
      "matchId": "c6435401-0c4e-443a-aab2-3248d7800e00",
      "evidence": "Compares PMV's drug candidate to Aprea's failed eprenetapopt to predict future failure.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 15,
      "from": 13,
      "beatId": "b60b9bcc-c14b-47d9-9883-5ca559055bcc",
      "arcName": "Overcoming the Monster",
      "arcSlug": "overcoming-monster",
      "beatName": "The Struggle",
      "beatSlug": "overcoming-monster-the-struggle",
      "evidence": "The document highlights the struggles PMV Pharma may face with its drug candidate.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}